A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2004
12/30/2004	US20040266770 treating diseases that are triggered by persistent angiogenesis; inhibition of the VEGF receptor
12/30/2004	US20040266764 Hydroxamic acid derivatives
12/30/2004	US20040266759 Possess antithrombotic and anticoagulant properties; example compound: 1-(5-Chlorobenzo[b]furan-2-ylsulphonyl)-4-[4-(4-pyridyl)benzoyl]piperazine
12/30/2004	US20040266755 Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
12/30/2004	US20040266750 Beta-lactamyl vasopressin v1aantagonists
12/30/2004	US20040266736 Particularly preferred inhibitors are low molecular weight substances unable to cross the blood/brain barrier, and act systemically and not centrally
12/30/2004	US20040266733 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1)
12/30/2004	US20040266720 Splice-region antisense composition and method
12/30/2004	US20040266717 Administering polynucleotide capable of modulating an electrical property in a standard cardiac electrophysiological assay; expressing the polynucleotide in the mammal to prevent or treat the cardiac arrhythmia
12/30/2004	US20040266716 Administering polynucleotide capable of modulating an electrical property in a standard cardiac electrophysiological assay; expressing the polynucleotide in the mammal to prevent or treat the cardiac arrhythmia
12/30/2004	US20040266698 Pyrane derivatives as both ace-and nep-inhibitors
12/30/2004	US20040266696 activating neovascularization by administering heptapeptides having replacements in the amino acid sequence; antiischemic agents; regeneration and maintenance of artificial bones
12/30/2004	US20040266694 Angiogenesis inhibitor induced by vascular endothelial growth factor
12/30/2004	US20040266687 Antiproliferative agents; antiinflammatory agents; angiogenesis inhibitors; anticancer agents
12/30/2004	US20040266679 Isolated ucleic acid; nucleotide sequence coding protein; detection moderators of kinase peptide
12/30/2004	US20040266675 Transgenic aniomal nmodels; screening; administering peptide
12/30/2004	US20040266661 Method for reducing hypertension and heart failure
12/30/2004	US20040266660 Hdl for the treatment of stroke and other ischemic conditions
12/30/2004	US20040265979 Novel macrophage foam cell formation inhibitor fka-25 and process for producing the same
12/30/2004	US20040265971 Cytokine for use in stem cell propagation and treatment ot cardiovascular, bone, nervous system and inflammatory disorders
12/30/2004	US20040265968 Tissue plasminogen activator-like protease
12/30/2004	US20040265927 Phospho-amino acid end groups interact with receptors on antigen-presenting cells; for treatment of T-cell mediated disorders (autoimmune conditions), inflammatory disorders, neurodegenerative disorders, and endothelial dysfunction disorders
12/30/2004	US20040265890 a polypeptide of given amino acid sequence; use as drug target for gastrointestinal disorders; fusion proteins; diagnosis
12/30/2004	US20040265885 Peptide nucleic acid (PNA) derivatives which carry one or more phosphoryl radicals at the N terminus of the PNA backbone; can be purified using efficient methods such as chromatography or electrophoresis; use as pharmaceuticals and diagnostic agents
12/30/2004	US20040265841 Analyzing mutations in Myosin Light Chain 2a; titin-related diseases; drug screening; animal models; knockout cells; transgenic zebrafish; antibodies
12/30/2004	US20040265466 Oil composition
12/30/2004	US20040265399 plant extracts used for prevention or treatment of lesions caused by estrogen deficiency
12/30/2004	US20040265392 Nanoparticles comprising biologically active tnf which is immobilized on the same
12/30/2004	US20040265382 Methylsulfonylphenyl or phenylsulfonamide derivatives having ring selected from cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine; celecoxib and rofecoxib; administered for pain; oral drug delivery
12/30/2004	US20040265358 Modified methionine rich food products and process for their manufacture
12/30/2004	US20040265311 Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity
12/30/2004	US20040265303 Anti-CCR2 antibodies and methods of use therefor
12/30/2004	US20040265300 Targeting cancer cell; induction or prevention of apoptosis in eukaryotic cells; a fusion peptide contains a viral apoptotic peptide and an antibody fragment; recombinant host cell comprising the vector, encoding chimeric polypeptide; bioassay monitoring apoptosis activity; drug target
12/30/2004	US20040265299 Comprising dextrin, starch, peach resin and magnesium stearate; use in hyperthyroidism therapy; reduce serum thyroid hormones level by binding thyroid hormones which is excreted to intestinal tract; hormone inhibitors
12/30/2004	US20040261190 Hydrazono-malonitriles
12/29/2004	WO2004113562A1 Method for assaying lkb1 phosphorylation activity
12/29/2004	WO2004113515A2 Tissue modeling in embryonic stem (es) cell system
12/29/2004	WO2004113509A1 Lactobacillus casei lc2w strain and its use in antihypertensive aspect
12/29/2004	WO2004113384A1 Use of a vegf receptor gene or gene product
12/29/2004	WO2004113367A1 Peptide having apoptosis-inhibiting activity
12/29/2004	WO2004113359A1 Pyrazole derivative, drug composition containing the same and production intermediate therefor
12/29/2004	WO2004113332A1 Nasal preparations
12/29/2004	WO2004113331A1 Novel compounds that modulate pparϝ type receptors, and use thereof in cosmetic or pharmaceutical compositions
12/29/2004	WO2004113303A1 INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF
12/29/2004	WO2004113300A1 Novel tricyclic heterocycle compound
12/29/2004	WO2004112839A2 Specific high-relaxivity conjugate compounds for magnetic resonance imaging
12/29/2004	WO2004112809A1 Composition for lowering serum uric acid level
12/29/2004	WO2004112777A1 Composition for prevention/treatment for varicose vein
12/29/2004	WO2004098713A3 Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4)
12/29/2004	WO2004096152A3 In situ gelling self-reactive materials for embolization
12/29/2004	WO2004089964A8 Lipid-regulating agent and use thereof
12/29/2004	WO2004085396A8 Preventive or therapeutic agent for ischemia/reperfusion injury, organ preservative, and screening method
12/29/2004	WO2004084932A3 Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
12/29/2004	WO2004009091A8 Purine derivatives as liver x receptor agonists
12/29/2004	WO2003103671A8 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/29/2004	WO2003045984A3 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance
12/29/2004	WO2003015797A8 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
12/29/2004	WO2002043648A3 Compounds active at the glucocorticoid receptor ii
12/29/2004	WO2000061774A3 Bone morphogenic proteins
12/29/2004	EP1491632A2 Anti-alphavbeta3 humanized monoclonal antibodies
12/29/2004	EP1491541A1 Pyridazinone aldose reductase inhibitors
12/29/2004	EP1491540A1 Pyridazinone aldose reductase inhibitors
12/29/2004	EP1491537A1 Hydroxymorpholinone derivative and medicinal use thereof
12/29/2004	EP1491533A2 Quinoline-and naphthalenecarboxamides, pharmaceutical compositions thereof and their use as calpain inhibitors
12/29/2004	EP1491532A1 Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetyloholine receptors
12/29/2004	EP1491207A1 Novel screening method
12/29/2004	EP1491194A1 Vdac regulator
12/29/2004	EP1491193A1 Therapeutic combinations comprising amlodipine and atorvastatin
12/29/2004	EP1491192A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
12/29/2004	EP1491093A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
12/29/2004	EP1490696A2 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
12/29/2004	EP1490492A2 Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
12/29/2004	EP1490474A2 Method for producing pseudo islets
12/29/2004	EP1490405A2 ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
12/29/2004	EP1490401A1 Vegf peptides and their use
12/29/2004	EP1490386A2 Novel polypeptides and nucleic acids encoding the same
12/29/2004	EP1490371A1 Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same
12/29/2004	EP1490366A1 Novel alkoxypyridine-derivatives
12/29/2004	EP1490365A1 Azaindoles as inhibitors of c-jun n-terminal kinases
12/29/2004	EP1490364A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
12/29/2004	EP1490361A1 Polycyclic compounds as potent alpha2-adrenoceptor antagonists
12/29/2004	EP1490360A1 Thiazolidinedione derivatives and pharmaceutical composition comprising the same
12/29/2004	EP1490356A1 (3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
12/29/2004	EP1490354A1 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity
12/29/2004	EP1490343A1 New aryl imidazoles and related compounds as c5a receptor modulators
12/29/2004	EP1490341A1 Novel adamantane derivatives
12/29/2004	EP1490339A1 Novel chalcone derivatives and uses thereof
12/29/2004	EP1490335A2 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/29/2004	EP1490317A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
12/29/2004	EP1490120A1 Embolization
12/29/2004	EP1490111A2 Edg-receptor agonists for the treatment of hypertension
12/29/2004	EP1490108A2 Drg11-responsive (dragon) gene family
12/29/2004	EP1490107A1 Modulating angiogenesis
12/29/2004	EP1490097A1 Use of botulinum toxin for treating cardiovascular diseases
12/29/2004	EP1490093A1 Methods and compositions for the treatment of ischemia
12/29/2004	EP1490080A1 A process for the extraction of anthocyanins from black rice and composition thereof
12/29/2004	EP1490076A2 Novel metabolic targets and markers
12/29/2004	EP1490072A1 Novel therapeutical use of agonist ligands specific to g2a receptor
12/29/2004	EP1490071A2 Theraputic methods and uses of sapogenins and their derivatives
12/29/2004	EP1490070A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy

1 ... 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 ... 1595